Immunome Inc. (IMNM) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Immunome Inc.'s filing signal turned negative.

Immunome, Inc. is a biotechnology company focused on developing targeted oncology therapies, aiming to build a portfolio of differentiated clinical assets. The company leverages its expertise in antibody-drug conjugates (ADCs) and other oncology therapeutics for discovery, design, development, manufacturing, and commercialization. Its pipeline includes three clinical assets: Varegacestat (a gamma secretase inhibitor for desmoid tumors), IM-1021 (a ROR1 ADC), and IM-3050 (a FAP-targeted radioligand therapy). Immunome also has three preclinical solid tumor ADCs with anticipated 2026 IND submissions and numerous early-stage ADCs. The company's strategy involves advancing Varegacestat towards potential commercialization, leveraging its ADC capabilities for pipeline progression, and pursuing selective business development opportunities.

The company has not generated revenue from product sales. Historically, revenue has been generated through collaboration agreements, such as the one with AbbVie, which terminated in July 2025. Future revenue is expected to come from the commercialization of its product candidates.